A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

Clinical trial NCT05836896 · RECRUITING

Trial details

NCT number: NCT05836896
Sponsor: Technische Universität Dresden
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplasms Relapsed Diffuse Large B-cell Lymphoma (DLBCL)Refractory Diffuse Large B-cell Lymphoma (DLBCL)Multiple Myeloma, Refractory Multiple Myeloma in Relapse

Start date: 2024-02-15
Primary completion: 2027-06-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.